We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves Dual Melanoma Treatment in First for Immuno-Oncology
FDA Approves Dual Melanoma Treatment in First for Immuno-Oncology
The FDA has cleared Bristol-Myers Squibb’s new mixed-drug regimen for the treatment of advanced melanoma, in a first-ever approval of an immune-oncology combination.